View Financial HealthelectroCore 配当と自社株買い配当金 基準チェック /06electroCore配当金を支払った記録がありません。主要情報n/a配当利回り-0.6%バイバック利回り総株主利回り-0.6%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 15electroCore, Inc. Announces Publication in JAMA Highlighting Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in FibromyalgiaelectroCore, Inc. announced the publication of new clinical findings in JAMA Network Open titled, Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With Fibromyalgia: A Cluster Randomized Clinical Trial. The study evaluated the use of a modified Quell device, an FDA-authorized nonpharmacological wearable stimulation device, when added to outpatient physical therapy (“PT”) for people with fibromyalgia. The trial enrolled 384 participants [that completed baseline data collection], including 191 individuals in the PT-Quell group and 193 individuals in the PT-only group. At day 60, reduction in movement-evoked pain was significantly greater in the PT-Quell group compared with the PT-only group, (between-group difference, -1.2 points [95% CI, -1.6 to -0.7]; P<.001), and statistically significant improvements favoring the PT-Quell group were also observed across several other secondary measures, including resting pain, pain interference, movement-evoked fatigue, resting fatigue, and fibromyalgia impact (FIQR) during the randomized phase. The benefits of Quell were observed within 30 days and were sustained for up to six months. Among respondents, 81% reported finding Quell helpful, and 55% continued to use Quell daily.Reported Earnings • May 07First quarter 2026 earnings released: US$0.59 loss per share (vs US$0.47 loss in 1Q 2025)First quarter 2026 results: US$0.59 loss per share (further deteriorated from US$0.47 loss in 1Q 2025). Revenue: US$9.58m (up 43% from 1Q 2025). Net loss: US$5.27m (loss widened 37% from 1Q 2025). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Apr 29electroCore, Inc. to Report Q1, 2026 Results on May 06, 2026electroCore, Inc. announced that they will report Q1, 2026 results After-Market on May 06, 2026お知らせ • Apr 09Electrocore Inc Announces First Patient Enrollment in Investigator-Led Study of Gammacore nVNS for PTSDElectroCore, Inc. announced the enrollment of the first eight patients in a clinical study being conducted by Acacia Clinics in collaboration with the Vagus Nerve Society. The study is designed to evaluate the safety and effectiveness of electroCore’s gammaCore non-invasive vagus nerve stimulation (nVNS) device as an adjunctive treatment for symptoms associated with PTSD. The study is expected to enroll up to 40 adult participants and will assess outcomes over a 12-week treatment period. The primary safety endpoint is the incidence of treatment-related serious adverse events, and the primary efficacy endpoint is the change from baseline in the Clinician-Administered PTSD Scale (CAPS-5) total score at 12 weeks. Secondary endpoints include changes in PTSD Checklist (PCL-5) scores and Clinical Global Impression (CGI) ratings. The study is sponsored by the Vagus Nerve Society, with electroCore providing an educational grant and gammaCore devices. The study is anticipated to run for approximately 10 months and is intended to generate preliminary safety and effectiveness data to inform future research in neuropsychiatric applications of nVNS.お知らせ • Apr 01ElectroCore Inc Announces Publication Highlighting Benefits Of Non-Invasive Vagus Nerve Stimulation In Patients With Mild Traumatic Brain Injury And PTSDElectroCore, Inc. announced the publication of new clinical findings in Frontiers in Neuroscience titled “Adjunctive non-invasive vagus nerve stimulation for chronic mild traumatic brain injury with comorbid post-traumatic stress disorder: a post-hoc analysis” by Drs. Michael Ament, Peter Staats, Norianne Theresa Ingram, and Emily Leonard, demonstrating the potential benefits of adjunctive non-invasive vagus nerve stimulation (nVNS) in patients with chronic mild traumatic brain injury (mTBI) and comorbid post-traumatic stress disorder (PTSD). The publication reports results from a post-hoc analysis of 35 patients with chronic mTBI and PTSD. The analysis showed that adjunctive nVNS significantly reduced overall symptom burden, with observed improvements across cognitive, affective, and somatic domains. The study population represented a high-symptom-burden cohort commonly associated with persistent and difficult-to-treat neurobehavioral symptoms. The full article can be accessed here: Frontiers: nVNS for mTBI and PTSD. These findings contribute to the growing body of evidence supporting the therapeutic potential of nVNS in patients with chronic mTBI and comorbid PTSD.Major Estimate Revision • Mar 26Consensus EPS estimates fall by 54%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$42.6m to US$42.0m. Losses expected to increase from US$0.93 per share to US$1.44. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target broadly unchanged at US$19.80. Share price fell 6.2% to US$6.15 over the past week.Breakeven Date Change • Mar 23Forecast to breakeven in 2028The 5 analysts covering electroCore expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 37% per year to 2027. The company is expected to make a profit of US$5.57m in 2028. Average annual earnings growth of 62% is required to achieve expected profit on schedule.Reported Earnings • Mar 21Third quarter 2025 earnings released: US$0.40 loss per share (vs US$0.31 loss in 3Q 2024)Third quarter 2025 results: US$0.40 loss per share (further deteriorated from US$0.31 loss in 3Q 2024). Revenue: US$8.69m (up 33% from 3Q 2024). Net loss: US$3.41m (loss widened 36% from 3Q 2024). Revenue is forecast to grow 20% p.a. on average during the next 4 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Price Target Changed • Mar 20Price target decreased by 7.9% to US$19.47Down from US$21.14, the current price target is an average from 5 analysts. New target price is 211% above last closing price of US$6.25. Stock is down 22% over the past year. The company is forecast to post a net loss per share of US$1.72 next year compared to a net loss per share of US$1.59 last year.お知らせ • Mar 20+ 2 more updateselectroCore, Inc. Provides Revenue Guidance for the Full Year of 2026electroCore, Inc. provided revenue guidance for the full year of 2026. For the period, the company expects revenue of approximately 30% annual revenue growth over 2025.お知らせ • Mar 09electroCore, Inc. to Report Q4, 2025 Results on Mar 19, 2026electroCore, Inc. announced that they will report Q4, 2025 results After-Market on Mar 19, 2026New Risk • Jan 26New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$14m Forecast net loss in 3 years: US$2.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$1.1m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$2.8m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (US$59.7m market cap).Breakeven Date Change • Jan 26No longer forecast to breakevenThe 5 analysts covering electroCore no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$2.13m in 2027. New consensus forecast suggests the company will make a loss of US$4.86m in 2027.お知らせ • Jan 21electroCore, Inc. Provides Earnings Guidance for the Fourth Quarter and Year Ended December 31, 2025electroCore, Inc. provided earnings guidance for the fourth quarter and year ended December 31, 2025. The company anticipated reporting fourth quarter 2025 revenue is anticipated to be approximately $9.0 - $9.2 million, which would represent approximately 30% growth over fourth quarter of 2024. The company anticipated reporting record full year 2025 revenue of approximately $31.8 - $32.0 million. This would represent approximately 26% growth over full-year 2024 revenue of $25.2 million.New Risk • Jan 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$1.1m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (US$52.4m market cap).分析記事 • Jan 09electroCore, Inc.'s (NASDAQ:ECOR) Price Is Right But Growth Is LackingYou may think that with a price-to-sales (or "P/S") ratio of 1.3x electroCore, Inc. ( NASDAQ:ECOR ) is a stock worth...Reported Earnings • Nov 07Second quarter 2025 earnings released: US$0.44 loss per share (vs US$0.38 loss in 2Q 2024)Second quarter 2025 results: US$0.44 loss per share (further deteriorated from US$0.38 loss in 2Q 2024). Revenue: US$7.38m (up 20% from 2Q 2024). Net loss: US$3.67m (loss widened 38% from 2Q 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.New Risk • Nov 06New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$13m Forecast net loss in 2 years: US$5.9m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$5.9m net loss in 2 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (US$37.9m market cap).Breakeven Date Change • Nov 06No longer forecast to breakevenThe 5 analysts covering electroCore no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$16.4m in 2027. New consensus forecast suggests the company will make a loss of US$4.12m in 2027.お知らせ • Oct 23electroCore, Inc. to Report Q3, 2025 Results on Nov 05, 2025electroCore, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 05, 2025お知らせ • Oct 18electroCore, Inc. announced that it has received $1.856 million in fundingOn October 17, 2025, electroCore, Inc closed the transaction. the transaction included participation from 3 Investors.お知らせ • Oct 02electroCore, Inc. Announces the Publication of A Peer-Reviewed Study in Frontiers in Neurology Demonstrating the Effectiveness of gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) in Reducing Persistent Post-Concussion SymptomselectroCore, Inc. announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI). The article, entitled "Non-invasive vagus nerve stimulating is associated with the reduction in persistent post-concussion symptoms: an observational study," found that adjunctive use of gammaCore with standard care was associated with significant and clinically meaningful improvements across multiple domains of the Neurobehavioral Symptom Inventory (NSI). The study included 102 patients with persistent symptoms following mTBI. Patients experienced significant reductions in 16 of 22 symptom categories, including post-traumatic headache, dizziness, difficulty concentrating, and depression. Approximately 34% of patients reported meaningful improvement in at least half of their persistent symptoms. Importantly, improvements were observed both in patients treated within three months of injury and in those whose symptoms had persisted for over a year, suggesting that nVNS may be beneficial regardless of time since injury.お知らせ • Sep 30electroCore Announces Reimbursement Approval for gammaCore by RIZIV/INAMI in BelgiumelectroCore, Inc. announced that gammaCore Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV /INAMI) in Belgium. Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on strong clinical evidence supporting the therapy's efficacy and cost-effectiveness and ensures broader access for Belgian patients. This achievement was made possible through the leadership and commitment of Silvert Medical, electroCore's distribution partner in Belgium. Silvert Medical leveraged their local expertise and strong provider relationships, playing a key role in securing reimbursement. Silvert Medical remains a vital partner in supporting the rollout of gammaCore in Belgium and is committed to extending access to gammaCore in neighboring countries.お知らせ • Sep 05electroCore, Inc. Announces Management ChangeselectroCore, Inc. announced the departure of Peter Cuneo from the Board of Directors and that Thomas J. Errico, MD, has been elected to succeed Mr. Cuneo as Chairman of the Board, effective September 2, 2025. Mr. Cuneo will continue as a strategic advisor to the Company.お知らせ • Sep 04electroCore, Inc. Announces Board ChangeselectroCore, Inc. announced that Elena Bonfiglioli, an accomplished healthcare executive, has been appointed to electroCore’s Board of Directors, effective September 2, 2025. Ms. Bonfiglioli’s appointment follows the retirement from the Board of Peter Cuneo. Ms. Bonfiglioli has been working in the health sector for more than two decades. She currently serves as Microsoft’s Global Business Leader for Healthcare, Pharma Life Sciences, and the International clinical applications’ solutions, responsible for go-to-market, commercial, and partnerships, enabling artificial intelligence (“AI”) transformation initiatives in health providers, payors and Life Sciences’ organizations globally. Since 2023, Ms. Bonfiglioli has been a Member of the Drug Information Association (“DIA”) for Europe, Middle East & Africa Regional Advisory Council, and serves as a board member of several startups in Europe and the Middle East and as advisor for biopharma organizations. Ms. Bonfiglioli was selected twice as one of the top 50 AI Innovators by Intelligent Health and was one of the founding members of the Holomedicine Association; and Vice Chair of the DIGITALEUROPE Executive Council for Healthcare since its creation in 2021. Ms. Bonfiglioli was a champion for secondary use of data to enhance research and activate the power of data to save lives. She recently joined the Board of The Women Health Initiative, a community powered by Kearney. She is active in the field of longevity and champions the shift to health enhanced by data and AI.分析記事 • Aug 24It's Down 27% But electroCore, Inc. (NASDAQ:ECOR) Could Be Riskier Than It LookselectroCore, Inc. ( NASDAQ:ECOR ) shares have retraced a considerable 27% in the last month, reversing a fair amount of...Recent Insider Transactions • Aug 14Founder & Independent Director recently bought US$67k worth of stockOn the 11th of August, Thomas Errico bought around 15k shares on-market at roughly US$4.47 per share. This transaction amounted to 7.0% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Thomas has been a buyer over the last 12 months, purchasing a net total of US$194k worth in shares.お知らせ • Aug 12electroCore, Inc. Announces Appointment of Kelly Benning as Senior Vice President of Truvaga, Effective July 21, 2025electroCore, Inc. announced that Kelly Benning has been hired as the Senior Vice President of Truvaga, effective July 21, 2025.Ms. Benning, who brings almost three decades of leadership experience across digital health, AI-enabled technologies, and consumer wellness, will lead electroCore’s consumer wellness division. Ms. Benning has successfully brought pioneering digital health products to market, including the first and only FDA-cleared watch to monitor blood pressure, delivering breakthrough solutions and expertly navigating the commercialization process. Her interest in AI and machine-learning has led her to drive continual innovation and consistent market adoption of technology at the intersection of healthcare, data, and consumer experience.Throughout her career, Ms. Benning has worked with a multitude of consumer retailers, payors, providers, and healthcare enterprises to bring clinically impactful and commercially successful products to market. She currently serves as Senior Vice President of Truvaga, electroCore’s digital wellness platform, where she leads strategy, operations, and growth. Prior to joining electroCore, Ms. Benning held executive leadership roles including President at LiveMetric, Vice President of Sales at IBM Watson Health, and senior roles at CipherHealth, Savonix, Healthgrades, and National Jewish Health. Ms. Benning holds a Bachelor of Arts in Kinesiology and Exercise Science from the University of Colorado Boulder.お知らせ • Aug 09electroCore, Inc Provides Earnings Guidance for the Full Year 2025electroCore, Inc. provided earnings guidance for the full year 2025. for the year, the company expects total revenue to be approximately $30.0 million and net cash usage for the remainder of the year to be between approximately $3.9 and $4.4 million.分析記事 • Aug 09Analysts Have Made A Financial Statement On electroCore, Inc.'s (NASDAQ:ECOR) Second-Quarter ReportNasdaqCM:ECOR 1 Year Share Price vs Fair Value Explore electroCore's Fair Values from the Community and select yours...Reported Earnings • Aug 08Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2025 results: US$0.44 loss per share (further deteriorated from US$0.38 loss in 2Q 2024). Revenue: US$7.38m (up 20% from 2Q 2024). Net loss: US$3.67m (loss widened 38% from 2Q 2024). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 35%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.お知らせ • Aug 06electroCore, Inc. Appoints James C. Theofilos to its Board of Directors, Effective August 1, 2025electroCore, Inc. announced that James C. Theofilos has been appointed to the Board of Directors, effective August 1, 2025. Mr. Theofilos has been a Senior Finance Manager within the Azure and artificial intelligence division of Microsoft Corporation since October 2023. In this role, Mr. Theofilos is the Go-to-Market Finance Lead across Microsoft’s AI Apps & Agents team, which includes all of Microsoft’s AI models, GitHub Copilot, Copilot Studio, and other products that aim to deliver the full value of AI & Agents. Previously, Mr. Theofilos held various finance positions at Microsoft including his position as the Finance Lead for Microsoft’s Global Healthcare & Life Sciences Sales team, which included exposure to the Health Providers, Payors, Pharma and Med Tech industry verticals. Prior to that, Mr. Theofilos consulted as a Group Project Manager at VICI Properties Inc. Mr. Theofilos holds an M.S. in Finance and a B.S.B.A. in Finance from Washington University in Saint Louis.お知らせ • Jul 23electroCore, Inc. to Report Q2, 2025 Results on Aug 06, 2025electroCore, Inc. announced that they will report Q2, 2025 results After-Market on Aug 06, 2025お知らせ • Jul 18electroCore, Inc., Annual General Meeting, Sep 02, 2025electroCore, Inc., Annual General Meeting, Sep 02, 2025.分析記事 • Jul 10Further Upside For electroCore, Inc. (NASDAQ:ECOR) Shares Could Introduce Price Risks After 43% BounceThe electroCore, Inc. ( NASDAQ:ECOR ) share price has done very well over the last month, posting an excellent gain of...お知らせ • May 16Happy Holstein Management, LLC Provides Information to the electroCore, Inc.On May 14, 2025, Happy Holstein Management, LLC announced that they are evaluating the feasibility of a change in the present board of directors or management of electroCore, Inc, including plans or proposals to nominate one or more director candidates, to amend the Company's charter and bylaws to remove the classified board, and other proposals to improve the corporate governance and transparency at the Company. Consistent with their investment purpose and subject to any applicable confidentiality obligations, one or more Happy Holstein Management, LLC or their representatives may engage in communications regarding the Company with other persons, including, without limitation, one or more shareholders of the Company, one or more officers of the Company and/or one or more members of the Board of Directors of the Company.Breakeven Date Change • May 12Forecast to breakeven in 2027The 4 analysts covering electroCore expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$16.4m in 2027. Average annual earnings growth of 62% is required to achieve expected profit on schedule.Price Target Changed • May 11Price target decreased by 13% to US$21.88Down from US$25.20, the current price target is an average from 5 analysts. New target price is 371% above last closing price of US$4.65. Stock is down 32% over the past year. The company is forecast to post a net loss per share of US$1.30 next year compared to a net loss per share of US$1.59 last year.Reported Earnings • May 10First quarter 2025 earnings: EPS and revenues miss analyst expectationsFirst quarter 2025 results: US$0.47 loss per share. Revenue: US$6.72m (up 23% from 1Q 2024). Net loss: US$3.86m (loss widened 10.0% from 1Q 2024). Revenue missed analyst estimates by 3.0%. Earnings per share (EPS) also missed analyst estimates by 5.2%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.お知らせ • May 08electroCore, Inc. Provides Preliminary Revenue Guidance for Year Ending December 2025electroCore, Inc. provided preliminary revenue guidance for year ending December 2025. For the year, the company expects total revenue to be approximately $30.0 million.お知らせ • Apr 30electroCore, Inc. to Report Q1, 2025 Results on May 07, 2025electroCore, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025新しいナラティブ • Apr 06Quell, gammaCore And Truvaga Will Expand US And Global Markets Strategic expansions through acquisitions and partnerships are poised to bolster revenue streams and commercialize new products, particularly in the healthcare sector. Breakeven Date Change • Apr 04No longer forecast to breakevenThe 3 analysts covering electroCore no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.09m in 2026. New consensus forecast suggests the company will make a loss of US$805.5k in 2026.Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Tricia Wilber was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Mar 26Market Cool On electroCore, Inc.'s (NASDAQ:ECOR) Revenues Pushing Shares 59% LowerThe electroCore, Inc. ( NASDAQ:ECOR ) share price has fared very poorly over the last month, falling by a substantial...Major Estimate Revision • Mar 19Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$36.4m to US$32.6m. Forecast losses increased from -US$0.475 to -US$1.24 per share. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target broadly unchanged at US$25.20. Share price fell 38% to US$8.01 over the past week.New Risk • Mar 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (US$59.4m market cap).Reported Earnings • Mar 13Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: US$1.59 loss per share (improved from US$3.42 loss in FY 2023). Revenue: US$25.2m (up 57% from FY 2023). Net loss: US$11.9m (loss narrowed 37% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.9%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 06electroCore, Inc. to Report Q4, 2024 Results on Mar 12, 2025electroCore, Inc. announced that they will report Q4, 2024 results After-Market on Mar 12, 2025New Risk • Mar 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$97.9m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$677k net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$97.9m market cap).お知らせ • Mar 01electroCore, Inc. Announces Resignation of Charles S. Theofilos as A Class III Director of the Board, as A Member of the Compensation Committee of the Board, and as A Member of the Nominating and Governance CommitOn February 24, 2025, Charles S. Theofilos, M.D., a member of the Board of Directors of electroCore, Inc. resigned as a Class III director of the Board, as a member of the Compensation Committee of the Board, and as a member of the Nominating and Governance Committee of the Board, in each case effective immediately. In connection with Dr. Theofilos’ resignation, on February 28, 2025, the Board decreased the size of the Board from eight to seven members, effective immediately.お知らせ • Jan 25electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market OfferingNew Risk • Jan 16New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$13m Forecast net loss in 2 years: US$677k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$677k net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change).分析記事 • Dec 18Why Investors Shouldn't Be Surprised By electroCore, Inc.'s (NASDAQ:ECOR) 27% Share Price SurgeDespite an already strong run, electroCore, Inc. ( NASDAQ:ECOR ) shares have been powering on, with a gain of 27% in...お知らせ • Dec 18electroCore, Inc. (NasdaqCM:ECOR) entered into an agreement and plan of merger to acquire NeuroMetrix, Inc. (NasdaqCM:NURO).electroCore, Inc. (NasdaqCM:ECOR) entered into an agreement and plan of merger to acquire NeuroMetrix, Inc. (NasdaqCM:NURO) on December 17, 2024. At the effective time of the Merger (the “Effective Time”), each share of common stock, par value $0.0001 per share, of the Company (the “Company Common Stock”) outstanding immediately prior to the Effective Time, shall be cancelled and cease to exist and shall be converted into the right to receive (i) an amount in cash (the “Per Share Cash Consideration’) equal to a pro rata share of the Company’s balance of Net Cash (as determined pursuant to the Merger Agreement) at the Effective Time, after deduction of certain pro rata payments that will be due in accordance with the MRIP (as defined below), without interest and (ii) one contingent value right (a “CVR"), which shall represent the right to receive the Contingent Payments (as defined below) subject to the terms and conditions set forth in the CVR Agreement. Under the terms of the merger agreement, a subsidiary of electroCore will merge with NeuroMetrix and NeuroMetrix will become a wholly owned subsidiary of electroCore. Upon termination of the Merger Agreement under specified circumstances, the NeuroMetrix will be required to pay electroCore a termination fee of $500,000. Consummation of the Merger is subject to customary closing conditions, including, without limitation, the absence of certain legal impediments, the approval by the holders of a majority of the outstanding shares of NeuroMetrix Common Stock entitled to vote on the Merger, the determination of Net Cash pursuant to the Merger Agreement, and the filing by the NeuroMetrix of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close late in the first quarter of 2025. Ira Kotel and Ilan Katz of Dentons US LLP acted as legal advisors to electroCore. Megan Gates of Covington& Burling LLP acted as legal advisor to NeuroMetrix in the transaction.お知らせ • Nov 30electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market OfferingNew Risk • Nov 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Shareholders have been diluted in the past year (7.4% increase in shares outstanding). Market cap is less than US$100m (US$87.7m market cap).Price Target Changed • Nov 15Price target increased by 10% to US$25.10Up from US$22.75, the current price target is an average from 5 analysts. New target price is 129% above last closing price of US$10.94. Stock is up 78% over the past year. The company is forecast to post a net loss per share of US$1.48 next year compared to a net loss per share of US$3.42 last year.お知らせ • Oct 23electroCore, Inc. to Report Q3, 2024 Results on Nov 13, 2024electroCore, Inc. announced that they will report Q3, 2024 results After-Market on Nov 13, 2024分析記事 • Oct 08electroCore, Inc. (NASDAQ:ECOR) Soars 34% But It's A Story Of Risk Vs RewardelectroCore, Inc. ( NASDAQ:ECOR ) shareholders would be excited to see that the share price has had a great month...分析記事 • Sep 25We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...Major Estimate Revision • Aug 14Consensus estimates of losses per share improve by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from US$24.5m to US$25.3m. EPS estimate increased from -US$1.52 per share to -US$1.36 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target of US$23.10 unchanged from last update. Share price fell 2.1% to US$5.97 over the past week.Breakeven Date Change • Aug 11Forecast to breakeven in 2026The 5 analysts covering electroCore expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 48% per year to 2025. The company is expected to make a profit of US$1.49m in 2026. Average annual earnings growth of 70% is required to achieve expected profit on schedule.Reported Earnings • Aug 09Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: US$0.38 loss per share (improved from US$1.03 loss in 2Q 2023). Revenue: US$6.14m (up 73% from 2Q 2023). Net loss: US$2.66m (loss narrowed 46% from 2Q 2023). Revenue exceeded analyst estimates by 9.6%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • Jul 31electroCore, Inc. to Report Q2, 2024 Results on Aug 07, 2024electroCore, Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024お知らせ • Jul 18electroCore, Inc., Annual General Meeting, Sep 03, 2024electroCore, Inc., Annual General Meeting, Sep 03, 2024.お知らせ • Jun 26electroCore Announces the Commercial Launch of TAC-STIM™?electroCore, Inc. announced the Commercial Off the Shelf (COTS) availability of the next generation TAC-STIM™?, a non-invasive vagus nerve stimulator (nVNS) designed in partnership with the US military to enhance human performance exclusively for active-duty military use. TAC-STIM is a cutting-edge device that can accelerate learning and improve mood and cognitive performance. TAC-STim is a portable, easy-to-use tool that leverages electroCore's patented technology to deliver precise and effective vagus nerve stimulation, helping war fighters and operators learn new tasks, increase readiness and mitigate fatigue across a range of high-pressure operational environments. TAC-STIM was originally developed in close collaboration with the 711th Human Performance Wing at the Air Force Research Laboratory (AFRL), Wright-Patterson AFB, OH, as part of the United States Department of Defense Biotech Optimized for Operational Solutions and tactics (BOOST) program. Independent testing by AFRL and Air Force Special Operations Command consistently demonstrated its capabilities across a range of operational settings. electroCore continues to participate in collaborative research to further enhance TAC-STIMs operational utility and showcase how TAC-STIM can enhance performance, reduce fatigue, and accelerate training without adverse effects. Key benefits of TAC-STIM include: Improve performance and combat fatigue for 12-24 hours under extreme conditions; 20-35% faster learning of complex material; Enhance ability to multi-task; Significantly decreased fatigue and increased focus.Breakeven Date Change • Jun 24Forecast to breakeven in 2026The 5 analysts covering electroCore expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 50% per year to 2025. The company is expected to make a profit of US$1.79m in 2026. Average annual earnings growth of 69% is required to achieve expected profit on schedule.お知らせ • Jun 08+ 1 more updateelectroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million.electroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million. Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 225,000 Price\Range: $6.429 Transaction Features: Registered Direct Offeringお知らせ • Jun 05+ 1 more updateelectroCore, Inc. announced a financing transactionelectroCore, Inc. announced a private placement of 1,208,310 common shares and warrants on June 3, 2024. The warrants can be exercisable into an aggregate of 604,150 shares of common stock. The transaction is expected to close on June 5, 2024.お知らせ • May 06electroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and ComplianceelectroCore, Inc. announced that on May 1, 2024, Donald Melnikoff joined electroCore as the Company’s SVP, Engineering, Regulatory, and Compliance; the Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Mr. Melnikoff in connection with the commencement of his employment.お知らせ • May 03electroCore, Inc. to Report Q1, 2024 Results on May 08, 2024electroCore, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024お知らせ • Apr 30electroCore, Inc. Announces Results of Truvaga Plus Consumer StudyelectroCore, Inc. announced the results of its most recent Truvaga Plus consumer study conducted earlier this year. Based on a 30-day in-home use test by an independent third-party research firm, Truvaga Plus helped its users improve sleep, focus, stress, energy, and mood. 39 participants were instructed to use the Truvaga Plus product at home twice a day for 30 days to assess the product's benefits, efficacy, and overall user experience. Self-assessment evaluations were reported after 7 and 30 days. After 30 days, users reported the following: 82% felt calmer; 82% felt mentally healthier; 77% felt more alert; 77% felt more relaxed; 74% felt they sleep better; 74% felt their mood improved; and 67% had more energy. Of those that felt they slept better, 72% reported they received between 30 minutes to 2+ hours or more sleep each night. After the study completed, 87% of users said they were likely to continue to use Truvaga Plus for ongoing overall wellness benefits.お知らせ • Apr 10electroCore, Inc. Announces the Launch of Truvaga Plus® for General WellnesselectroCore, Inc. announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on www.truvaga.com beginning April 8, 2024. Key features of Truvaga Plus include: Mobile App Connectivity: Empowering users to control sessions, plan schedules, and track progress conveniently through integrated mobile application. Unlimited Sessions: Providing users with the flexibility for prolonged usage and extended benefits, ensuring continuous support for achieving optimal wellness. Rechargeable: Enhancing sustainability and user convenience, Truvaga Plus features a rechargeable design for uninterrupted usage. Compact Design: Sleeker, smaller, and more portable, the new design of Truvaga Plus ensures enhanced user comfort and convenience.お知らせ • Mar 06electroCore, Inc. to Report Q4, 2023 Results on Mar 13, 2024electroCore, Inc. announced that they will report Q4, 2023 results After-Market on Mar 13, 2024お知らせ • Dec 15electroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the BoardOn December 8, 2023, the board of directors (the “ Board”) of electroCore, Inc. (the “ Company”) appointed Charles S. Theofilos, M.D., as a new Class III member of the Board. The term of each Class III director lasts until the Company’s 2024 annual meeting of stockholders. In connection with the appointment of Dr. Theofilos to the Board, the size of the Board was increased by resolution of the Board from seven members to eight members on December 8, 2023. Dr. Theofilos is a retired neurosurgeon who founded The Spine Center in Palm Beach Gardens, FL in 1996. He also founded and serves as President of Theo Concepts, LLC and Founder of The Theo Group, a family office. Previously, he served as Co-Director of the Neuroscience Center, Chairman of Neurosurgery, and Chairman of Cranial and Spinal Surgery, at JFK Medical Center in Atlantis, Florida, Director of Spine Surgery at Jupiter Medical Center, and Chairman of Neurosurgery at Palm Beach Gardens Medical Center. Dr. Theofilos has been a founder, director and/or investor in a number of early-stage medical device and healthcare companies, including K2Medical, SpineCore LLC and electroCore, LLC, a predecessor of the Company. Dr. Theofilos received an M.D. from Emory University School of Medicine, a B.A. in biology from Emory University, and a GMP (General Management Program) from The Wharton School of The University of Pennsylvania.お知らせ • Oct 26Electrocore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation (Nvns) for Treatment of Symptoms of GastroparesiselectroCore, Inc. announced top line data from an abstract being presented as an oral podium presentation at the 2023 American College of Gastroenterology Annual Meeting held in Vancouver, Canada from October 23- 25, 2023 regarding the potential for nVNS to decrease the use of acute rescue medications for exacerbations of nausea due to Gastroparesis (GP) or Functional Dyspepsia (FD). Many gastrointestinal disorders can cause nausea and vomiting, of which the most well-known is gastroparesis, a digestive disorder in which the stomach empties slowly. The symptoms of gastroparesis can range from mild to severe, requiring prolonged hospitalizations and interventions, and causing life-threatening complications which can significantly affect the quality of life in affected individuals. It is estimated that close to 6 million Americans suffer from gastroparesis which is more common in women than men. The economic impact of gastroparesis can be substantial, with studies reporting 11% of patients disabled due to their gastroparesis symptoms, while another 28.5% reported a loss of yearly income. Nausea without slow gastric emptying may be even more common and has been referred to by many names, including chronic unexplained nausea and vomiting (CUNV), gastroparesis-like syndrome (GLS), functional vomiting, and vomiting of unexplained etiology (VUE). Many of these patients can be classified as having functional dyspepsia (FD) which is a disorder that may affect 10% of the US population. Non-Invasive Vagal Nerve Stimulation (nVNS) Reduces Nausea Rescue Medication in Patients with Gastroparesis andRelated Disorders, with Additional Benefits on Multiple Other Associated Symptoms This pilot study (n=41) included patients =15 years of age with ongoing GP or FD symptoms for a period of =3 months. The focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.お知らせ • Oct 10electroCore, Inc. to Report Q3, 2023 Results on Nov 08, 2023electroCore, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023お知らせ • Sep 28electroCore, Inc. Announces the Publication of Two Peer Reviewed Publication of Two Peer Reviewed Publications Supporting the Use of Gammacore ( Non-Invasive Vagus Nerve Stimulation; nVNS) in Patients with Post Traumatic Stress DisorderelectroCore, Inc. announced the publication of two peer reviewed publications supporting the use of gammaCore (non-invasive vagal nerve stimulation; nVNS) in patients with posttraumatic stress disorder (PTSD). The first paper entitled "Effect of transcutaneous cervical vagus nerve stimulation on declarative and working memory in patients with Posttraumatic Stress Disorder (PTSD): A pilot study" wasauthored by Tilendra Choudhary and the second, "Transcutaneous vagal nerve stimulation modulates stress-induced plasma ghrelin levels: A double-blind, randomized, sham-controlled trial" was written by Kasra Moazzami. Both studies were conducted at Emory University and were published in the peer reviewed Journal of Affective Stress Disorder. The prevalence of PTSD in the United States is estimated at 10-12% in women and 5-6% in men, and the prevalence in veterans can be twice as high. Ghrelin is a neuropeptide hypothesized to be involved in the stress response but also plays an important role in the regulation of appetite. Biomarkers that can be easily assessed can help identify likely responders to a specific therapy and are critical to improving the patient experience and decreasing health care costs. The results of this study showed that TCVNS, in conjunction with personalized traumatic scripts, resulted in lower ghrelin levels (265.2 +- 143.6 pg/ml vs 478.7 +- 349.2 pg/ml, P = 0.01). Additionally, after completing the public speaking and mental math tests, ghrelin levels were found to be lower in the group receiving TCVNS (293.3 +- 102.4 pg/ml vs 540.3 +- 203.9 pg/ml, P =0.009).2 Ghrelin may be involved in behaviors like stress-induced over-eating, suggesting future avenues of research into the potential for nVNS in the treatment of obesity and possibly stress-induced eating disorders.お知らせ • Aug 24electroCore, Inc. Announces Dismissal of All Litigation Related to Its 2018 Initial Public OfferingelectroCore, Inc. announced that it has been completely vindicated in the securities class actions over the company’s 2018 initial public offering brought in the federal and state courts of New Jersey. The litigation has concluded without any finding of wrongdoing or liability, nor any payment, by electroCore. On July 13, 2023, District Judge Zahid N. Quraishi of the United States District for the District of New Jersey, dismissed the second amended class action complaint alleging violations of the Securities Act and the Securities Exchange Act. In a detailed opinion, Judge Quraishi considered each of the plaintiff’s allegations of misrepresentations and omissions in the prospectus for the IPO and in other public statements and filings in 2018-19 and held the plaintiff has not adequately pleaded any alleged untrue statement or that any allegedly omitted information rendered any factual statement untrue. Judge Quraishi also found that the plaintiff failed to adequately allege that electroCore intended to mislead or omit information. Judge Quraishi permitted the plaintiff thirty days to try to amend their complaint for a third time but warned that “while the Plaintiff can change the words of the Complaint, Plaintiff cannot change the words of the Prospectus.” Judge Quraishi’s dismissal followed the prior dismissal of the first amended complaint, also in a detailed opinion assessing each of plaintiff’s allegations, by District Judge Anne E. Thompson, on August 13, 2021. The plaintiff decided not to amend their complaint a third time and did not appeal the District Court’s ruling within the required time. Thus, the federal court litigation is over. This follows the termination earlier this year of litigation over the IPO and electroCore’s statements initiated in 2019 in the Somerset County, New Jersey Superior Court. That case was twice dismissed with prejudice, and on May 15, 2023, the Appellate Division of the New Jersey Superior Court unanimously affirmed the dismissal with prejudice. The time for further appeals in that case also has expired. Thus, the litigation over the initial public offering has been brought to a close with a complete vindication of electroCore, its directors and its management in their handling of the 2018 IPO.お知らせ • Aug 11electroCore, Inc. Reiterates Revenue Guidance for the Year 2023electroCore, Inc. reiterated revenue guidance for the year 2023. The company reiterates its revenue guidance of $14.0 million to $15.0 million for calendar year 2023.お知らせ • Aug 03electroCore, Inc. to Report Q2, 2023 Results on Aug 09, 2023electroCore, Inc. announced that they will report Q2, 2023 results After-Market on Aug 09, 2023お知らせ • Jul 12Electrocore Provides Earnings Guidance for the Second Quarter and Full Fiscal Year 2023electroCore Provided earnings guidance for the Second Quarter and full fiscal year 2023 . For the quarter, Company,anticipates reporting record quarterly revenue of approximately $3,550,000 for the quarter ended June 30, 2023. This would represent approximately 65% growth over second quarter 2022 revenue of approximately $2,157,000For the year, Company reiterated its revenue guidance of $14.0 Million -$15.0 Million.お知らせ • Jun 06electroCore, Inc., Annual General Meeting, Aug 04, 2023electroCore, Inc., Annual General Meeting, Aug 04, 2023, at 09:00 US Eastern Standard Time. Agenda: To elect one Class II director to the Board for a three-year term of office expiring at the 2026 Annual Meeting of Stockholders; and to ratify the selection of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.お知らせ • May 05electroCore, Inc. Reiterates Revenue Guidance for the Year Ending December 31, 2023electroCore, Inc. reiterated revenue guidance for the year ending December 31, 2023. The Company reiterated its revenue guidance of $14.0 million to $15.0 million for the year ending December 31, 2023.お知らせ • Jan 18electroCore, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2022electroCore, Inc. provided preliminary earnings guidance for the fourth quarter and full year of 2022. For the year, the company anticipates reporting record full year 2022 revenue of approximately $8.5 million. This would represent approximately 57% growth over full-year 2021 revenue of $5.5 million.For the quarter, the company's revenue is anticipated to be approximately $2.5 million, which would represent approximately 68% growth over fourth quarter of 2021.Seeking Alpha • Oct 14electroCore sees Q3 revenue below consensuselectroCore (NASDAQ:ECOR) reported Friday its third quarter revenue is estimated to be about $1.98M, well below the consensus of $2.30M. The preliminary guidance represents a 33% growth over the company's year-ago quarter's revenue. It is to include Government Channels revenue of $1.15M; Commercial, $0.41M; and Outside of the U.S. $0.42M. The company ended the quarter with $21.9M in cash and cash equivalents. Final results of Q3 2022 slated to be announced in November.Seeking Alpha • Sep 21electroCore is issued 4 new U.S. patents in nVNS therapyelectroCore (NASDAQ:ECOR) has secured four new U.S. patents in its non-invasive vagus nerve stimulation and other technologies. Dan Goldberger, CEO of the commercial-stage medical device company, stated Wednesday "These new patents support our mobile connectivity platform, by using mobile devices coupled with a stimulator to deliver nVNS therapy. The addition of these patents underscores our commitment to advancing therapy beyond those who suffer from migraines and cluster headaches, and we look forward to continuing to explore the role of nVNS for various conditions." It includes: Mobile Phone for Treating a Patient with Dementia; Devices and Methods for Remote Therapy and Patient Monitoring; Electrical Nerve Stimulation to Treat Gastroparesis, Functional Dyspepsia, and Other Functional Gastrointestinal Disorders; Stimulator for Use with a Mobile Device.Seeking Alpha • Jul 12electroCore sees Q2 revenue estimate higher than consensuselectroCore (NASDAQ:ECOR) expects Q2 revenue to come in more than $2.1M which is a 11% increase from Q1 2022 and ~65% Y/Y growth; this is compared to analysts consensus estimates of $2M. During the quarter, the company expects to recognize revenue of ~$1.2M (vs. $1.26M in Q1 of 2022) post the Department of Veterans Affairs and Department of Defense originating prescriptions for company's gammaCore products. It sees commercial revenue of ~$465K dominated by cash pay initiatives and representing ~68% Q/Q increase and 347% Y/Y growth. Revenue outside of U.S. seen at ~$466K marking ~53% Q/Q increase and ~20% Y/Y increase. Q2 ended with ~$26.6M of cash and equivalents, compared to $29.9M as of the end of Q1 of 2022. Q2 earnings scheduled for August 2022. Shares trading 5.1% higher premarket.Recent Insider Transactions • Jun 17Co-Founder recently bought US$56k worth of stockOn the 13th of June, Joseph Errico bought around 100k shares on-market at roughly US$0.56 per share. This was the largest purchase by an insider in the last 3 months. This was Joseph's only on-market trade for the last 12 months.Reported Earnings • May 06First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: US$0.079 loss per share. Revenue: US$1.90m (up 58% from 1Q 2021). Net loss: US$5.58m (loss widened 3.7% from 1Q 2021). Revenue exceeded analyst estimates by 7.4%. Earnings per share (EPS) missed analyst estimates by 21%. Over the next year, revenue is forecast to grow 64%, compared to a 9.4% growth forecast for the industry in the US.分析記事 • Apr 29We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...決済の安定と成長配当データの取得安定した配当: ECORの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: ECORの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場electroCore 配当利回り対市場ECOR 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ECOR)n/a市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Medical Equipment)2.2%アナリスト予想 (ECOR) (最長3年)n/a注目すべき配当: ECORは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: ECORは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: ECORの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: ECORが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/18 12:34終値2026/05/15 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋electroCore, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Fozia AhmedBrookline Capital MarketsTyler BussianBrookline Capital MarketsBrian Kemp DolliverBrookline Capital Markets7 その他のアナリストを表示
お知らせ • May 15electroCore, Inc. Announces Publication in JAMA Highlighting Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in FibromyalgiaelectroCore, Inc. announced the publication of new clinical findings in JAMA Network Open titled, Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With Fibromyalgia: A Cluster Randomized Clinical Trial. The study evaluated the use of a modified Quell device, an FDA-authorized nonpharmacological wearable stimulation device, when added to outpatient physical therapy (“PT”) for people with fibromyalgia. The trial enrolled 384 participants [that completed baseline data collection], including 191 individuals in the PT-Quell group and 193 individuals in the PT-only group. At day 60, reduction in movement-evoked pain was significantly greater in the PT-Quell group compared with the PT-only group, (between-group difference, -1.2 points [95% CI, -1.6 to -0.7]; P<.001), and statistically significant improvements favoring the PT-Quell group were also observed across several other secondary measures, including resting pain, pain interference, movement-evoked fatigue, resting fatigue, and fibromyalgia impact (FIQR) during the randomized phase. The benefits of Quell were observed within 30 days and were sustained for up to six months. Among respondents, 81% reported finding Quell helpful, and 55% continued to use Quell daily.
Reported Earnings • May 07First quarter 2026 earnings released: US$0.59 loss per share (vs US$0.47 loss in 1Q 2025)First quarter 2026 results: US$0.59 loss per share (further deteriorated from US$0.47 loss in 1Q 2025). Revenue: US$9.58m (up 43% from 1Q 2025). Net loss: US$5.27m (loss widened 37% from 1Q 2025). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Apr 29electroCore, Inc. to Report Q1, 2026 Results on May 06, 2026electroCore, Inc. announced that they will report Q1, 2026 results After-Market on May 06, 2026
お知らせ • Apr 09Electrocore Inc Announces First Patient Enrollment in Investigator-Led Study of Gammacore nVNS for PTSDElectroCore, Inc. announced the enrollment of the first eight patients in a clinical study being conducted by Acacia Clinics in collaboration with the Vagus Nerve Society. The study is designed to evaluate the safety and effectiveness of electroCore’s gammaCore non-invasive vagus nerve stimulation (nVNS) device as an adjunctive treatment for symptoms associated with PTSD. The study is expected to enroll up to 40 adult participants and will assess outcomes over a 12-week treatment period. The primary safety endpoint is the incidence of treatment-related serious adverse events, and the primary efficacy endpoint is the change from baseline in the Clinician-Administered PTSD Scale (CAPS-5) total score at 12 weeks. Secondary endpoints include changes in PTSD Checklist (PCL-5) scores and Clinical Global Impression (CGI) ratings. The study is sponsored by the Vagus Nerve Society, with electroCore providing an educational grant and gammaCore devices. The study is anticipated to run for approximately 10 months and is intended to generate preliminary safety and effectiveness data to inform future research in neuropsychiatric applications of nVNS.
お知らせ • Apr 01ElectroCore Inc Announces Publication Highlighting Benefits Of Non-Invasive Vagus Nerve Stimulation In Patients With Mild Traumatic Brain Injury And PTSDElectroCore, Inc. announced the publication of new clinical findings in Frontiers in Neuroscience titled “Adjunctive non-invasive vagus nerve stimulation for chronic mild traumatic brain injury with comorbid post-traumatic stress disorder: a post-hoc analysis” by Drs. Michael Ament, Peter Staats, Norianne Theresa Ingram, and Emily Leonard, demonstrating the potential benefits of adjunctive non-invasive vagus nerve stimulation (nVNS) in patients with chronic mild traumatic brain injury (mTBI) and comorbid post-traumatic stress disorder (PTSD). The publication reports results from a post-hoc analysis of 35 patients with chronic mTBI and PTSD. The analysis showed that adjunctive nVNS significantly reduced overall symptom burden, with observed improvements across cognitive, affective, and somatic domains. The study population represented a high-symptom-burden cohort commonly associated with persistent and difficult-to-treat neurobehavioral symptoms. The full article can be accessed here: Frontiers: nVNS for mTBI and PTSD. These findings contribute to the growing body of evidence supporting the therapeutic potential of nVNS in patients with chronic mTBI and comorbid PTSD.
Major Estimate Revision • Mar 26Consensus EPS estimates fall by 54%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$42.6m to US$42.0m. Losses expected to increase from US$0.93 per share to US$1.44. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target broadly unchanged at US$19.80. Share price fell 6.2% to US$6.15 over the past week.
Breakeven Date Change • Mar 23Forecast to breakeven in 2028The 5 analysts covering electroCore expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 37% per year to 2027. The company is expected to make a profit of US$5.57m in 2028. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
Reported Earnings • Mar 21Third quarter 2025 earnings released: US$0.40 loss per share (vs US$0.31 loss in 3Q 2024)Third quarter 2025 results: US$0.40 loss per share (further deteriorated from US$0.31 loss in 3Q 2024). Revenue: US$8.69m (up 33% from 3Q 2024). Net loss: US$3.41m (loss widened 36% from 3Q 2024). Revenue is forecast to grow 20% p.a. on average during the next 4 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Mar 20Price target decreased by 7.9% to US$19.47Down from US$21.14, the current price target is an average from 5 analysts. New target price is 211% above last closing price of US$6.25. Stock is down 22% over the past year. The company is forecast to post a net loss per share of US$1.72 next year compared to a net loss per share of US$1.59 last year.
お知らせ • Mar 20+ 2 more updateselectroCore, Inc. Provides Revenue Guidance for the Full Year of 2026electroCore, Inc. provided revenue guidance for the full year of 2026. For the period, the company expects revenue of approximately 30% annual revenue growth over 2025.
お知らせ • Mar 09electroCore, Inc. to Report Q4, 2025 Results on Mar 19, 2026electroCore, Inc. announced that they will report Q4, 2025 results After-Market on Mar 19, 2026
New Risk • Jan 26New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$14m Forecast net loss in 3 years: US$2.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$1.1m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$2.8m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (US$59.7m market cap).
Breakeven Date Change • Jan 26No longer forecast to breakevenThe 5 analysts covering electroCore no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$2.13m in 2027. New consensus forecast suggests the company will make a loss of US$4.86m in 2027.
お知らせ • Jan 21electroCore, Inc. Provides Earnings Guidance for the Fourth Quarter and Year Ended December 31, 2025electroCore, Inc. provided earnings guidance for the fourth quarter and year ended December 31, 2025. The company anticipated reporting fourth quarter 2025 revenue is anticipated to be approximately $9.0 - $9.2 million, which would represent approximately 30% growth over fourth quarter of 2024. The company anticipated reporting record full year 2025 revenue of approximately $31.8 - $32.0 million. This would represent approximately 26% growth over full-year 2024 revenue of $25.2 million.
New Risk • Jan 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Negative equity (-US$1.1m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (US$52.4m market cap).
分析記事 • Jan 09electroCore, Inc.'s (NASDAQ:ECOR) Price Is Right But Growth Is LackingYou may think that with a price-to-sales (or "P/S") ratio of 1.3x electroCore, Inc. ( NASDAQ:ECOR ) is a stock worth...
Reported Earnings • Nov 07Second quarter 2025 earnings released: US$0.44 loss per share (vs US$0.38 loss in 2Q 2024)Second quarter 2025 results: US$0.44 loss per share (further deteriorated from US$0.38 loss in 2Q 2024). Revenue: US$7.38m (up 20% from 2Q 2024). Net loss: US$3.67m (loss widened 38% from 2Q 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
New Risk • Nov 06New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$13m Forecast net loss in 2 years: US$5.9m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$5.9m net loss in 2 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (US$37.9m market cap).
Breakeven Date Change • Nov 06No longer forecast to breakevenThe 5 analysts covering electroCore no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$16.4m in 2027. New consensus forecast suggests the company will make a loss of US$4.12m in 2027.
お知らせ • Oct 23electroCore, Inc. to Report Q3, 2025 Results on Nov 05, 2025electroCore, Inc. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 05, 2025
お知らせ • Oct 18electroCore, Inc. announced that it has received $1.856 million in fundingOn October 17, 2025, electroCore, Inc closed the transaction. the transaction included participation from 3 Investors.
お知らせ • Oct 02electroCore, Inc. Announces the Publication of A Peer-Reviewed Study in Frontiers in Neurology Demonstrating the Effectiveness of gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) in Reducing Persistent Post-Concussion SymptomselectroCore, Inc. announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI). The article, entitled "Non-invasive vagus nerve stimulating is associated with the reduction in persistent post-concussion symptoms: an observational study," found that adjunctive use of gammaCore with standard care was associated with significant and clinically meaningful improvements across multiple domains of the Neurobehavioral Symptom Inventory (NSI). The study included 102 patients with persistent symptoms following mTBI. Patients experienced significant reductions in 16 of 22 symptom categories, including post-traumatic headache, dizziness, difficulty concentrating, and depression. Approximately 34% of patients reported meaningful improvement in at least half of their persistent symptoms. Importantly, improvements were observed both in patients treated within three months of injury and in those whose symptoms had persisted for over a year, suggesting that nVNS may be beneficial regardless of time since injury.
お知らせ • Sep 30electroCore Announces Reimbursement Approval for gammaCore by RIZIV/INAMI in BelgiumelectroCore, Inc. announced that gammaCore Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV /INAMI) in Belgium. Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on strong clinical evidence supporting the therapy's efficacy and cost-effectiveness and ensures broader access for Belgian patients. This achievement was made possible through the leadership and commitment of Silvert Medical, electroCore's distribution partner in Belgium. Silvert Medical leveraged their local expertise and strong provider relationships, playing a key role in securing reimbursement. Silvert Medical remains a vital partner in supporting the rollout of gammaCore in Belgium and is committed to extending access to gammaCore in neighboring countries.
お知らせ • Sep 05electroCore, Inc. Announces Management ChangeselectroCore, Inc. announced the departure of Peter Cuneo from the Board of Directors and that Thomas J. Errico, MD, has been elected to succeed Mr. Cuneo as Chairman of the Board, effective September 2, 2025. Mr. Cuneo will continue as a strategic advisor to the Company.
お知らせ • Sep 04electroCore, Inc. Announces Board ChangeselectroCore, Inc. announced that Elena Bonfiglioli, an accomplished healthcare executive, has been appointed to electroCore’s Board of Directors, effective September 2, 2025. Ms. Bonfiglioli’s appointment follows the retirement from the Board of Peter Cuneo. Ms. Bonfiglioli has been working in the health sector for more than two decades. She currently serves as Microsoft’s Global Business Leader for Healthcare, Pharma Life Sciences, and the International clinical applications’ solutions, responsible for go-to-market, commercial, and partnerships, enabling artificial intelligence (“AI”) transformation initiatives in health providers, payors and Life Sciences’ organizations globally. Since 2023, Ms. Bonfiglioli has been a Member of the Drug Information Association (“DIA”) for Europe, Middle East & Africa Regional Advisory Council, and serves as a board member of several startups in Europe and the Middle East and as advisor for biopharma organizations. Ms. Bonfiglioli was selected twice as one of the top 50 AI Innovators by Intelligent Health and was one of the founding members of the Holomedicine Association; and Vice Chair of the DIGITALEUROPE Executive Council for Healthcare since its creation in 2021. Ms. Bonfiglioli was a champion for secondary use of data to enhance research and activate the power of data to save lives. She recently joined the Board of The Women Health Initiative, a community powered by Kearney. She is active in the field of longevity and champions the shift to health enhanced by data and AI.
分析記事 • Aug 24It's Down 27% But electroCore, Inc. (NASDAQ:ECOR) Could Be Riskier Than It LookselectroCore, Inc. ( NASDAQ:ECOR ) shares have retraced a considerable 27% in the last month, reversing a fair amount of...
Recent Insider Transactions • Aug 14Founder & Independent Director recently bought US$67k worth of stockOn the 11th of August, Thomas Errico bought around 15k shares on-market at roughly US$4.47 per share. This transaction amounted to 7.0% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Thomas has been a buyer over the last 12 months, purchasing a net total of US$194k worth in shares.
お知らせ • Aug 12electroCore, Inc. Announces Appointment of Kelly Benning as Senior Vice President of Truvaga, Effective July 21, 2025electroCore, Inc. announced that Kelly Benning has been hired as the Senior Vice President of Truvaga, effective July 21, 2025.Ms. Benning, who brings almost three decades of leadership experience across digital health, AI-enabled technologies, and consumer wellness, will lead electroCore’s consumer wellness division. Ms. Benning has successfully brought pioneering digital health products to market, including the first and only FDA-cleared watch to monitor blood pressure, delivering breakthrough solutions and expertly navigating the commercialization process. Her interest in AI and machine-learning has led her to drive continual innovation and consistent market adoption of technology at the intersection of healthcare, data, and consumer experience.Throughout her career, Ms. Benning has worked with a multitude of consumer retailers, payors, providers, and healthcare enterprises to bring clinically impactful and commercially successful products to market. She currently serves as Senior Vice President of Truvaga, electroCore’s digital wellness platform, where she leads strategy, operations, and growth. Prior to joining electroCore, Ms. Benning held executive leadership roles including President at LiveMetric, Vice President of Sales at IBM Watson Health, and senior roles at CipherHealth, Savonix, Healthgrades, and National Jewish Health. Ms. Benning holds a Bachelor of Arts in Kinesiology and Exercise Science from the University of Colorado Boulder.
お知らせ • Aug 09electroCore, Inc Provides Earnings Guidance for the Full Year 2025electroCore, Inc. provided earnings guidance for the full year 2025. for the year, the company expects total revenue to be approximately $30.0 million and net cash usage for the remainder of the year to be between approximately $3.9 and $4.4 million.
分析記事 • Aug 09Analysts Have Made A Financial Statement On electroCore, Inc.'s (NASDAQ:ECOR) Second-Quarter ReportNasdaqCM:ECOR 1 Year Share Price vs Fair Value Explore electroCore's Fair Values from the Community and select yours...
Reported Earnings • Aug 08Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2025 results: US$0.44 loss per share (further deteriorated from US$0.38 loss in 2Q 2024). Revenue: US$7.38m (up 20% from 2Q 2024). Net loss: US$3.67m (loss widened 38% from 2Q 2024). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 35%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
お知らせ • Aug 06electroCore, Inc. Appoints James C. Theofilos to its Board of Directors, Effective August 1, 2025electroCore, Inc. announced that James C. Theofilos has been appointed to the Board of Directors, effective August 1, 2025. Mr. Theofilos has been a Senior Finance Manager within the Azure and artificial intelligence division of Microsoft Corporation since October 2023. In this role, Mr. Theofilos is the Go-to-Market Finance Lead across Microsoft’s AI Apps & Agents team, which includes all of Microsoft’s AI models, GitHub Copilot, Copilot Studio, and other products that aim to deliver the full value of AI & Agents. Previously, Mr. Theofilos held various finance positions at Microsoft including his position as the Finance Lead for Microsoft’s Global Healthcare & Life Sciences Sales team, which included exposure to the Health Providers, Payors, Pharma and Med Tech industry verticals. Prior to that, Mr. Theofilos consulted as a Group Project Manager at VICI Properties Inc. Mr. Theofilos holds an M.S. in Finance and a B.S.B.A. in Finance from Washington University in Saint Louis.
お知らせ • Jul 23electroCore, Inc. to Report Q2, 2025 Results on Aug 06, 2025electroCore, Inc. announced that they will report Q2, 2025 results After-Market on Aug 06, 2025
お知らせ • Jul 18electroCore, Inc., Annual General Meeting, Sep 02, 2025electroCore, Inc., Annual General Meeting, Sep 02, 2025.
分析記事 • Jul 10Further Upside For electroCore, Inc. (NASDAQ:ECOR) Shares Could Introduce Price Risks After 43% BounceThe electroCore, Inc. ( NASDAQ:ECOR ) share price has done very well over the last month, posting an excellent gain of...
お知らせ • May 16Happy Holstein Management, LLC Provides Information to the electroCore, Inc.On May 14, 2025, Happy Holstein Management, LLC announced that they are evaluating the feasibility of a change in the present board of directors or management of electroCore, Inc, including plans or proposals to nominate one or more director candidates, to amend the Company's charter and bylaws to remove the classified board, and other proposals to improve the corporate governance and transparency at the Company. Consistent with their investment purpose and subject to any applicable confidentiality obligations, one or more Happy Holstein Management, LLC or their representatives may engage in communications regarding the Company with other persons, including, without limitation, one or more shareholders of the Company, one or more officers of the Company and/or one or more members of the Board of Directors of the Company.
Breakeven Date Change • May 12Forecast to breakeven in 2027The 4 analysts covering electroCore expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 77% per year to 2026. The company is expected to make a profit of US$16.4m in 2027. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
Price Target Changed • May 11Price target decreased by 13% to US$21.88Down from US$25.20, the current price target is an average from 5 analysts. New target price is 371% above last closing price of US$4.65. Stock is down 32% over the past year. The company is forecast to post a net loss per share of US$1.30 next year compared to a net loss per share of US$1.59 last year.
Reported Earnings • May 10First quarter 2025 earnings: EPS and revenues miss analyst expectationsFirst quarter 2025 results: US$0.47 loss per share. Revenue: US$6.72m (up 23% from 1Q 2024). Net loss: US$3.86m (loss widened 10.0% from 1Q 2024). Revenue missed analyst estimates by 3.0%. Earnings per share (EPS) also missed analyst estimates by 5.2%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.
お知らせ • May 08electroCore, Inc. Provides Preliminary Revenue Guidance for Year Ending December 2025electroCore, Inc. provided preliminary revenue guidance for year ending December 2025. For the year, the company expects total revenue to be approximately $30.0 million.
お知らせ • Apr 30electroCore, Inc. to Report Q1, 2025 Results on May 07, 2025electroCore, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025
新しいナラティブ • Apr 06Quell, gammaCore And Truvaga Will Expand US And Global Markets Strategic expansions through acquisitions and partnerships are poised to bolster revenue streams and commercialize new products, particularly in the healthcare sector.
Breakeven Date Change • Apr 04No longer forecast to breakevenThe 3 analysts covering electroCore no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.09m in 2026. New consensus forecast suggests the company will make a loss of US$805.5k in 2026.
Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. Independent Director Tricia Wilber was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Mar 26Market Cool On electroCore, Inc.'s (NASDAQ:ECOR) Revenues Pushing Shares 59% LowerThe electroCore, Inc. ( NASDAQ:ECOR ) share price has fared very poorly over the last month, falling by a substantial...
Major Estimate Revision • Mar 19Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$36.4m to US$32.6m. Forecast losses increased from -US$0.475 to -US$1.24 per share. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target broadly unchanged at US$25.20. Share price fell 38% to US$8.01 over the past week.
New Risk • Mar 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (US$59.4m market cap).
Reported Earnings • Mar 13Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: US$1.59 loss per share (improved from US$3.42 loss in FY 2023). Revenue: US$25.2m (up 57% from FY 2023). Net loss: US$11.9m (loss narrowed 37% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.9%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 06electroCore, Inc. to Report Q4, 2024 Results on Mar 12, 2025electroCore, Inc. announced that they will report Q4, 2024 results After-Market on Mar 12, 2025
New Risk • Mar 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$97.9m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$677k net loss in 2 years). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$97.9m market cap).
お知らせ • Mar 01electroCore, Inc. Announces Resignation of Charles S. Theofilos as A Class III Director of the Board, as A Member of the Compensation Committee of the Board, and as A Member of the Nominating and Governance CommitOn February 24, 2025, Charles S. Theofilos, M.D., a member of the Board of Directors of electroCore, Inc. resigned as a Class III director of the Board, as a member of the Compensation Committee of the Board, and as a member of the Nominating and Governance Committee of the Board, in each case effective immediately. In connection with Dr. Theofilos’ resignation, on February 28, 2025, the Board decreased the size of the Board from eight to seven members, effective immediately.
お知らせ • Jan 25electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
New Risk • Jan 16New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$13m Forecast net loss in 2 years: US$677k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$677k net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change).
分析記事 • Dec 18Why Investors Shouldn't Be Surprised By electroCore, Inc.'s (NASDAQ:ECOR) 27% Share Price SurgeDespite an already strong run, electroCore, Inc. ( NASDAQ:ECOR ) shares have been powering on, with a gain of 27% in...
お知らせ • Dec 18electroCore, Inc. (NasdaqCM:ECOR) entered into an agreement and plan of merger to acquire NeuroMetrix, Inc. (NasdaqCM:NURO).electroCore, Inc. (NasdaqCM:ECOR) entered into an agreement and plan of merger to acquire NeuroMetrix, Inc. (NasdaqCM:NURO) on December 17, 2024. At the effective time of the Merger (the “Effective Time”), each share of common stock, par value $0.0001 per share, of the Company (the “Company Common Stock”) outstanding immediately prior to the Effective Time, shall be cancelled and cease to exist and shall be converted into the right to receive (i) an amount in cash (the “Per Share Cash Consideration’) equal to a pro rata share of the Company’s balance of Net Cash (as determined pursuant to the Merger Agreement) at the Effective Time, after deduction of certain pro rata payments that will be due in accordance with the MRIP (as defined below), without interest and (ii) one contingent value right (a “CVR"), which shall represent the right to receive the Contingent Payments (as defined below) subject to the terms and conditions set forth in the CVR Agreement. Under the terms of the merger agreement, a subsidiary of electroCore will merge with NeuroMetrix and NeuroMetrix will become a wholly owned subsidiary of electroCore. Upon termination of the Merger Agreement under specified circumstances, the NeuroMetrix will be required to pay electroCore a termination fee of $500,000. Consummation of the Merger is subject to customary closing conditions, including, without limitation, the absence of certain legal impediments, the approval by the holders of a majority of the outstanding shares of NeuroMetrix Common Stock entitled to vote on the Merger, the determination of Net Cash pursuant to the Merger Agreement, and the filing by the NeuroMetrix of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close late in the first quarter of 2025. Ira Kotel and Ilan Katz of Dentons US LLP acted as legal advisors to electroCore. Megan Gates of Covington& Burling LLP acted as legal advisor to NeuroMetrix in the transaction.
お知らせ • Nov 30electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.electroCore, Inc. has filed a Follow-on Equity Offering in the amount of $20 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
New Risk • Nov 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Shareholders have been diluted in the past year (7.4% increase in shares outstanding). Market cap is less than US$100m (US$87.7m market cap).
Price Target Changed • Nov 15Price target increased by 10% to US$25.10Up from US$22.75, the current price target is an average from 5 analysts. New target price is 129% above last closing price of US$10.94. Stock is up 78% over the past year. The company is forecast to post a net loss per share of US$1.48 next year compared to a net loss per share of US$3.42 last year.
お知らせ • Oct 23electroCore, Inc. to Report Q3, 2024 Results on Nov 13, 2024electroCore, Inc. announced that they will report Q3, 2024 results After-Market on Nov 13, 2024
分析記事 • Oct 08electroCore, Inc. (NASDAQ:ECOR) Soars 34% But It's A Story Of Risk Vs RewardelectroCore, Inc. ( NASDAQ:ECOR ) shareholders would be excited to see that the share price has had a great month...
分析記事 • Sep 25We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Major Estimate Revision • Aug 14Consensus estimates of losses per share improve by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from US$24.5m to US$25.3m. EPS estimate increased from -US$1.52 per share to -US$1.36 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target of US$23.10 unchanged from last update. Share price fell 2.1% to US$5.97 over the past week.
Breakeven Date Change • Aug 11Forecast to breakeven in 2026The 5 analysts covering electroCore expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 48% per year to 2025. The company is expected to make a profit of US$1.49m in 2026. Average annual earnings growth of 70% is required to achieve expected profit on schedule.
Reported Earnings • Aug 09Second quarter 2024 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2024 results: US$0.38 loss per share (improved from US$1.03 loss in 2Q 2023). Revenue: US$6.14m (up 73% from 2Q 2023). Net loss: US$2.66m (loss narrowed 46% from 2Q 2023). Revenue exceeded analyst estimates by 9.6%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • Jul 31electroCore, Inc. to Report Q2, 2024 Results on Aug 07, 2024electroCore, Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024
お知らせ • Jul 18electroCore, Inc., Annual General Meeting, Sep 03, 2024electroCore, Inc., Annual General Meeting, Sep 03, 2024.
お知らせ • Jun 26electroCore Announces the Commercial Launch of TAC-STIM™?electroCore, Inc. announced the Commercial Off the Shelf (COTS) availability of the next generation TAC-STIM™?, a non-invasive vagus nerve stimulator (nVNS) designed in partnership with the US military to enhance human performance exclusively for active-duty military use. TAC-STIM is a cutting-edge device that can accelerate learning and improve mood and cognitive performance. TAC-STim is a portable, easy-to-use tool that leverages electroCore's patented technology to deliver precise and effective vagus nerve stimulation, helping war fighters and operators learn new tasks, increase readiness and mitigate fatigue across a range of high-pressure operational environments. TAC-STIM was originally developed in close collaboration with the 711th Human Performance Wing at the Air Force Research Laboratory (AFRL), Wright-Patterson AFB, OH, as part of the United States Department of Defense Biotech Optimized for Operational Solutions and tactics (BOOST) program. Independent testing by AFRL and Air Force Special Operations Command consistently demonstrated its capabilities across a range of operational settings. electroCore continues to participate in collaborative research to further enhance TAC-STIMs operational utility and showcase how TAC-STIM can enhance performance, reduce fatigue, and accelerate training without adverse effects. Key benefits of TAC-STIM include: Improve performance and combat fatigue for 12-24 hours under extreme conditions; 20-35% faster learning of complex material; Enhance ability to multi-task; Significantly decreased fatigue and increased focus.
Breakeven Date Change • Jun 24Forecast to breakeven in 2026The 5 analysts covering electroCore expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 50% per year to 2025. The company is expected to make a profit of US$1.79m in 2026. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
お知らせ • Jun 08+ 1 more updateelectroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million.electroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million. Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 225,000 Price\Range: $6.429 Transaction Features: Registered Direct Offering
お知らせ • Jun 05+ 1 more updateelectroCore, Inc. announced a financing transactionelectroCore, Inc. announced a private placement of 1,208,310 common shares and warrants on June 3, 2024. The warrants can be exercisable into an aggregate of 604,150 shares of common stock. The transaction is expected to close on June 5, 2024.
お知らせ • May 06electroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and ComplianceelectroCore, Inc. announced that on May 1, 2024, Donald Melnikoff joined electroCore as the Company’s SVP, Engineering, Regulatory, and Compliance; the Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Mr. Melnikoff in connection with the commencement of his employment.
お知らせ • May 03electroCore, Inc. to Report Q1, 2024 Results on May 08, 2024electroCore, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024
お知らせ • Apr 30electroCore, Inc. Announces Results of Truvaga Plus Consumer StudyelectroCore, Inc. announced the results of its most recent Truvaga Plus consumer study conducted earlier this year. Based on a 30-day in-home use test by an independent third-party research firm, Truvaga Plus helped its users improve sleep, focus, stress, energy, and mood. 39 participants were instructed to use the Truvaga Plus product at home twice a day for 30 days to assess the product's benefits, efficacy, and overall user experience. Self-assessment evaluations were reported after 7 and 30 days. After 30 days, users reported the following: 82% felt calmer; 82% felt mentally healthier; 77% felt more alert; 77% felt more relaxed; 74% felt they sleep better; 74% felt their mood improved; and 67% had more energy. Of those that felt they slept better, 72% reported they received between 30 minutes to 2+ hours or more sleep each night. After the study completed, 87% of users said they were likely to continue to use Truvaga Plus for ongoing overall wellness benefits.
お知らせ • Apr 10electroCore, Inc. Announces the Launch of Truvaga Plus® for General WellnesselectroCore, Inc. announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on www.truvaga.com beginning April 8, 2024. Key features of Truvaga Plus include: Mobile App Connectivity: Empowering users to control sessions, plan schedules, and track progress conveniently through integrated mobile application. Unlimited Sessions: Providing users with the flexibility for prolonged usage and extended benefits, ensuring continuous support for achieving optimal wellness. Rechargeable: Enhancing sustainability and user convenience, Truvaga Plus features a rechargeable design for uninterrupted usage. Compact Design: Sleeker, smaller, and more portable, the new design of Truvaga Plus ensures enhanced user comfort and convenience.
お知らせ • Mar 06electroCore, Inc. to Report Q4, 2023 Results on Mar 13, 2024electroCore, Inc. announced that they will report Q4, 2023 results After-Market on Mar 13, 2024
お知らせ • Dec 15electroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the BoardOn December 8, 2023, the board of directors (the “ Board”) of electroCore, Inc. (the “ Company”) appointed Charles S. Theofilos, M.D., as a new Class III member of the Board. The term of each Class III director lasts until the Company’s 2024 annual meeting of stockholders. In connection with the appointment of Dr. Theofilos to the Board, the size of the Board was increased by resolution of the Board from seven members to eight members on December 8, 2023. Dr. Theofilos is a retired neurosurgeon who founded The Spine Center in Palm Beach Gardens, FL in 1996. He also founded and serves as President of Theo Concepts, LLC and Founder of The Theo Group, a family office. Previously, he served as Co-Director of the Neuroscience Center, Chairman of Neurosurgery, and Chairman of Cranial and Spinal Surgery, at JFK Medical Center in Atlantis, Florida, Director of Spine Surgery at Jupiter Medical Center, and Chairman of Neurosurgery at Palm Beach Gardens Medical Center. Dr. Theofilos has been a founder, director and/or investor in a number of early-stage medical device and healthcare companies, including K2Medical, SpineCore LLC and electroCore, LLC, a predecessor of the Company. Dr. Theofilos received an M.D. from Emory University School of Medicine, a B.A. in biology from Emory University, and a GMP (General Management Program) from The Wharton School of The University of Pennsylvania.
お知らせ • Oct 26Electrocore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation (Nvns) for Treatment of Symptoms of GastroparesiselectroCore, Inc. announced top line data from an abstract being presented as an oral podium presentation at the 2023 American College of Gastroenterology Annual Meeting held in Vancouver, Canada from October 23- 25, 2023 regarding the potential for nVNS to decrease the use of acute rescue medications for exacerbations of nausea due to Gastroparesis (GP) or Functional Dyspepsia (FD). Many gastrointestinal disorders can cause nausea and vomiting, of which the most well-known is gastroparesis, a digestive disorder in which the stomach empties slowly. The symptoms of gastroparesis can range from mild to severe, requiring prolonged hospitalizations and interventions, and causing life-threatening complications which can significantly affect the quality of life in affected individuals. It is estimated that close to 6 million Americans suffer from gastroparesis which is more common in women than men. The economic impact of gastroparesis can be substantial, with studies reporting 11% of patients disabled due to their gastroparesis symptoms, while another 28.5% reported a loss of yearly income. Nausea without slow gastric emptying may be even more common and has been referred to by many names, including chronic unexplained nausea and vomiting (CUNV), gastroparesis-like syndrome (GLS), functional vomiting, and vomiting of unexplained etiology (VUE). Many of these patients can be classified as having functional dyspepsia (FD) which is a disorder that may affect 10% of the US population. Non-Invasive Vagal Nerve Stimulation (nVNS) Reduces Nausea Rescue Medication in Patients with Gastroparesis andRelated Disorders, with Additional Benefits on Multiple Other Associated Symptoms This pilot study (n=41) included patients =15 years of age with ongoing GP or FD symptoms for a period of =3 months. The focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
お知らせ • Oct 10electroCore, Inc. to Report Q3, 2023 Results on Nov 08, 2023electroCore, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023
お知らせ • Sep 28electroCore, Inc. Announces the Publication of Two Peer Reviewed Publication of Two Peer Reviewed Publications Supporting the Use of Gammacore ( Non-Invasive Vagus Nerve Stimulation; nVNS) in Patients with Post Traumatic Stress DisorderelectroCore, Inc. announced the publication of two peer reviewed publications supporting the use of gammaCore (non-invasive vagal nerve stimulation; nVNS) in patients with posttraumatic stress disorder (PTSD). The first paper entitled "Effect of transcutaneous cervical vagus nerve stimulation on declarative and working memory in patients with Posttraumatic Stress Disorder (PTSD): A pilot study" wasauthored by Tilendra Choudhary and the second, "Transcutaneous vagal nerve stimulation modulates stress-induced plasma ghrelin levels: A double-blind, randomized, sham-controlled trial" was written by Kasra Moazzami. Both studies were conducted at Emory University and were published in the peer reviewed Journal of Affective Stress Disorder. The prevalence of PTSD in the United States is estimated at 10-12% in women and 5-6% in men, and the prevalence in veterans can be twice as high. Ghrelin is a neuropeptide hypothesized to be involved in the stress response but also plays an important role in the regulation of appetite. Biomarkers that can be easily assessed can help identify likely responders to a specific therapy and are critical to improving the patient experience and decreasing health care costs. The results of this study showed that TCVNS, in conjunction with personalized traumatic scripts, resulted in lower ghrelin levels (265.2 +- 143.6 pg/ml vs 478.7 +- 349.2 pg/ml, P = 0.01). Additionally, after completing the public speaking and mental math tests, ghrelin levels were found to be lower in the group receiving TCVNS (293.3 +- 102.4 pg/ml vs 540.3 +- 203.9 pg/ml, P =0.009).2 Ghrelin may be involved in behaviors like stress-induced over-eating, suggesting future avenues of research into the potential for nVNS in the treatment of obesity and possibly stress-induced eating disorders.
お知らせ • Aug 24electroCore, Inc. Announces Dismissal of All Litigation Related to Its 2018 Initial Public OfferingelectroCore, Inc. announced that it has been completely vindicated in the securities class actions over the company’s 2018 initial public offering brought in the federal and state courts of New Jersey. The litigation has concluded without any finding of wrongdoing or liability, nor any payment, by electroCore. On July 13, 2023, District Judge Zahid N. Quraishi of the United States District for the District of New Jersey, dismissed the second amended class action complaint alleging violations of the Securities Act and the Securities Exchange Act. In a detailed opinion, Judge Quraishi considered each of the plaintiff’s allegations of misrepresentations and omissions in the prospectus for the IPO and in other public statements and filings in 2018-19 and held the plaintiff has not adequately pleaded any alleged untrue statement or that any allegedly omitted information rendered any factual statement untrue. Judge Quraishi also found that the plaintiff failed to adequately allege that electroCore intended to mislead or omit information. Judge Quraishi permitted the plaintiff thirty days to try to amend their complaint for a third time but warned that “while the Plaintiff can change the words of the Complaint, Plaintiff cannot change the words of the Prospectus.” Judge Quraishi’s dismissal followed the prior dismissal of the first amended complaint, also in a detailed opinion assessing each of plaintiff’s allegations, by District Judge Anne E. Thompson, on August 13, 2021. The plaintiff decided not to amend their complaint a third time and did not appeal the District Court’s ruling within the required time. Thus, the federal court litigation is over. This follows the termination earlier this year of litigation over the IPO and electroCore’s statements initiated in 2019 in the Somerset County, New Jersey Superior Court. That case was twice dismissed with prejudice, and on May 15, 2023, the Appellate Division of the New Jersey Superior Court unanimously affirmed the dismissal with prejudice. The time for further appeals in that case also has expired. Thus, the litigation over the initial public offering has been brought to a close with a complete vindication of electroCore, its directors and its management in their handling of the 2018 IPO.
お知らせ • Aug 11electroCore, Inc. Reiterates Revenue Guidance for the Year 2023electroCore, Inc. reiterated revenue guidance for the year 2023. The company reiterates its revenue guidance of $14.0 million to $15.0 million for calendar year 2023.
お知らせ • Aug 03electroCore, Inc. to Report Q2, 2023 Results on Aug 09, 2023electroCore, Inc. announced that they will report Q2, 2023 results After-Market on Aug 09, 2023
お知らせ • Jul 12Electrocore Provides Earnings Guidance for the Second Quarter and Full Fiscal Year 2023electroCore Provided earnings guidance for the Second Quarter and full fiscal year 2023 . For the quarter, Company,anticipates reporting record quarterly revenue of approximately $3,550,000 for the quarter ended June 30, 2023. This would represent approximately 65% growth over second quarter 2022 revenue of approximately $2,157,000For the year, Company reiterated its revenue guidance of $14.0 Million -$15.0 Million.
お知らせ • Jun 06electroCore, Inc., Annual General Meeting, Aug 04, 2023electroCore, Inc., Annual General Meeting, Aug 04, 2023, at 09:00 US Eastern Standard Time. Agenda: To elect one Class II director to the Board for a three-year term of office expiring at the 2026 Annual Meeting of Stockholders; and to ratify the selection of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.
お知らせ • May 05electroCore, Inc. Reiterates Revenue Guidance for the Year Ending December 31, 2023electroCore, Inc. reiterated revenue guidance for the year ending December 31, 2023. The Company reiterated its revenue guidance of $14.0 million to $15.0 million for the year ending December 31, 2023.
お知らせ • Jan 18electroCore, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2022electroCore, Inc. provided preliminary earnings guidance for the fourth quarter and full year of 2022. For the year, the company anticipates reporting record full year 2022 revenue of approximately $8.5 million. This would represent approximately 57% growth over full-year 2021 revenue of $5.5 million.For the quarter, the company's revenue is anticipated to be approximately $2.5 million, which would represent approximately 68% growth over fourth quarter of 2021.
Seeking Alpha • Oct 14electroCore sees Q3 revenue below consensuselectroCore (NASDAQ:ECOR) reported Friday its third quarter revenue is estimated to be about $1.98M, well below the consensus of $2.30M. The preliminary guidance represents a 33% growth over the company's year-ago quarter's revenue. It is to include Government Channels revenue of $1.15M; Commercial, $0.41M; and Outside of the U.S. $0.42M. The company ended the quarter with $21.9M in cash and cash equivalents. Final results of Q3 2022 slated to be announced in November.
Seeking Alpha • Sep 21electroCore is issued 4 new U.S. patents in nVNS therapyelectroCore (NASDAQ:ECOR) has secured four new U.S. patents in its non-invasive vagus nerve stimulation and other technologies. Dan Goldberger, CEO of the commercial-stage medical device company, stated Wednesday "These new patents support our mobile connectivity platform, by using mobile devices coupled with a stimulator to deliver nVNS therapy. The addition of these patents underscores our commitment to advancing therapy beyond those who suffer from migraines and cluster headaches, and we look forward to continuing to explore the role of nVNS for various conditions." It includes: Mobile Phone for Treating a Patient with Dementia; Devices and Methods for Remote Therapy and Patient Monitoring; Electrical Nerve Stimulation to Treat Gastroparesis, Functional Dyspepsia, and Other Functional Gastrointestinal Disorders; Stimulator for Use with a Mobile Device.
Seeking Alpha • Jul 12electroCore sees Q2 revenue estimate higher than consensuselectroCore (NASDAQ:ECOR) expects Q2 revenue to come in more than $2.1M which is a 11% increase from Q1 2022 and ~65% Y/Y growth; this is compared to analysts consensus estimates of $2M. During the quarter, the company expects to recognize revenue of ~$1.2M (vs. $1.26M in Q1 of 2022) post the Department of Veterans Affairs and Department of Defense originating prescriptions for company's gammaCore products. It sees commercial revenue of ~$465K dominated by cash pay initiatives and representing ~68% Q/Q increase and 347% Y/Y growth. Revenue outside of U.S. seen at ~$466K marking ~53% Q/Q increase and ~20% Y/Y increase. Q2 ended with ~$26.6M of cash and equivalents, compared to $29.9M as of the end of Q1 of 2022. Q2 earnings scheduled for August 2022. Shares trading 5.1% higher premarket.
Recent Insider Transactions • Jun 17Co-Founder recently bought US$56k worth of stockOn the 13th of June, Joseph Errico bought around 100k shares on-market at roughly US$0.56 per share. This was the largest purchase by an insider in the last 3 months. This was Joseph's only on-market trade for the last 12 months.
Reported Earnings • May 06First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: US$0.079 loss per share. Revenue: US$1.90m (up 58% from 1Q 2021). Net loss: US$5.58m (loss widened 3.7% from 1Q 2021). Revenue exceeded analyst estimates by 7.4%. Earnings per share (EPS) missed analyst estimates by 21%. Over the next year, revenue is forecast to grow 64%, compared to a 9.4% growth forecast for the industry in the US.
分析記事 • Apr 29We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
